



NEONATAL MEDICATION PROTOCOLS

NEOSTIGMINE
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	NEOSTIGMINE
PRESENTATION:	Ampoule: 0.5mg/mL (500 microgram/mL) 2.5mg/mL (2500 microgram/mL)
ACTION & INDICATION:	An anticholinesterase used to reverse the effects of neuromuscular blocking drugs. It may also be used to test for, or to treat, neonatal myasthenia gravis.
DOSE:	Reversal of non-depolarising muscle relaxants. IV,IM: 50 - 80 microgram/kg/dose To be used in conjunction with atropine (20 microgram/kg/dose) Diluent: Sodium chloride 0.9%, glucose, glucose / saline.
PREPARATION:	Use undiluted, or dilute contents of 2.5mg ampoule to 16.5mL = 150 microgram/mL
ADMINISTRATION:	IV: Give over 1 minute
ADVERSE EFFECTS:	Muscle weakness, tremors, bradycardia, hypotension, respiratory depression, bronchospasm, diarrhoea, excessive salivation.
COMMENTS:	Contraindicated in patients with intestinal or urinary obstruction.
REFERENCES:	Paediatric Pharmacopoeia 13 th Ed Royal Children's Hospital Melbourne Neofax 2013 BNF for Children 2013
DATE:	October 2013